Here you will find a curated selection of top industry content related to Cellular, Acellular, and Matrix-like Products (CAMPS)

The American College of Clinical Wound Specialists is excited to announce its collaboration with the upcoming AVLS 38th Annual Congress, the largest vein and lymphatic medical conference in the United States. This four-day educational event will take place at the Sheraton Grand Chicago Riverwalk from October 10-13, 2024.

Medicare's proposed LCD for cellular tissue products (CTPs)/cellular, acellular, and matrix-like products (CAMPs) for Diabetic Foot Ulcers (DFUs) and Venous Leg Ulcers (VLUs) hinders patient access to essential treatment options, encourages unsafe, outdated practices and negatively impacts healing outcomes. Please join us in voicing your support to ensure patients will continue to have access to these essential wound care products.

PRESS RELEASE – Open letter to the Medicare Administrative Contractors (MACs) expressing concerns over the potential unfavorable impact on patient care resulting from their proposed draft cellular, acellular, and matrix-like products (CAMPs) local coverage determinations (LCDs).

As the US population continues to age, costs for hard-to-heal wounds are expected to rise and negatively contribute to the long-term financial stability of Medicare, which is currently labelled a ‘high-risk’ program by the US Government Accountability Office. 

Comorbidities, treatment patterns and outcomes of Medicare enrolees who developed venous leg ulcers (VLUs) were retrospectively evaluated. Patients diagnosed with chronic venous insufficiency (CVI) and a VLU were propensity matched into four groups based on their treatment regimen. 

Dr Thomas Serena discusses the consequences in real-time of not providing guidance on the minimal amount of evidence required to recommend a CAMP (cellular, acellular matrix-based product) for patients. He argues that more clinical evidence needs to be published to support their efficacy.